The Effect of Oral Supplementation of Chromium Picolinate on Liver Function, Oxidative index, Leptin and Resistin in Non-Alcoholic Fatty Liver Disease

Abstract

Non-alcoholic fatty liver (NAFLD) is one of the most common chronic metabolic diseases in the world. The prevalence of obesity, type 2 diabetes, and insulin resistance is closely linked to NAFLD. There is some evidence for the beneficial effects of chromium picolinate in NAFLD. Its beneficial effects have been shown to improve insulin sensitivity, reduce blood lipids and improve antioxidant status in laboratory and animal studies. Therefore, due to the lack of human studies in this case, the present study was designed and conducted to determine the effect of oral administration of chromium picolinate on on Liver Function, Oxidative Index, Leptin and Resistin in Non-Alcoholic Fatty Liver DiseaseMethods: In this double-blind randomized clinical trial, 46 patients with NAFLD were randomly assigned to receive 400 micrograms of chromium picolinate (in the form of two 200-pound chromium picolinate pills) and placebo (taking two placebo pills containing corn starch of similar weight and shape). Chromium picolinate tablets were administered for 12 weeks. Measurement indicators including weight, height and waist circumference (WC) and anthropometry including fat mass, lean mass and total body water were measured, and information on food intake and physical activity levels at the beginning and end of the study was. Data on dietary intake and physical activity level of the subjectswere assessed at the beginning and end of the study using 24 hour food intake and short form of international physical activity Questionnaire respectively. Blood pressure was also measured at the beginning and end of the study. Participant intravenous blood sample after fasting 14-12 hours for determination of whole blood glutathione peroxidase (GPX) levels, red blood cell superoxide dismutase (SOD) and then serum isolation and storage to determine serum leptin, resistin, malondialdehyde (MDA) serum levels. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) were taken from patients at the beginning and end of the study. Results: Of total 46 patients enrolled, 43 subjects completed the study (22 in the chromium picolinate group and 21 in the placebo group). Supplementation with chromium picolinate compared with the placebo group caused a significant increase in SOD (p = 0.037) enzyme activity and a significant decrease in serum MDA (p = 0.015) and serum leptin (p = 0.011) as well as a decrease. Weight (p = 0.037) and body fat mass compared to the placebo group. However, it had no effect on serum concentrations, resin, liver enzymes, antioxidant activity of GPX enzyme red blood cells and other components of blood pressure and blood pressure (p≥0.05). However, in the chromium picolinate group, after 12 weeks of supplementation, a significant decrease in liver enzymes was observed compared to the beginning of the study. Conclusion: The findings of our study suggested that the administration of chromium picolinate (400 μg / day) for 12 weeks in patients with NAFLD has beneficialeffects on the oxidative stress, some anthropometric indices and leptin, but had no effect on liver enzymes